Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2014

01.12.2014 | Original Article

Effects of combined treatment of α-tocopherol, l-ascorbic acid, selenium and zinc on bleomycin, etoposide and cisplatin-induced alterations in testosterone synthesis pathway in rats

verfasst von: Narayana Kilarkaje

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the effects of therapeutically relevant dose levels of bleomycin, etoposide and cisplatin (BEP) on testicular steroidogenic enzymes, and possible protective effects of an antioxidant cocktail (AC).

Methods

Adult Sprague–Dawley rats received BEP with or without the AC (α-tocopherol, l-ascorbic acid, selenium and zinc) for either (a) 4 days (short term; 1.5, 15 and 3 mg/kg), or (b) three cycles of 21 days each (0.75, 7.5 and 1.5 mg/kg), or (c) the three cycles with a 63-day recovery period. The expression of steroidogenic enzymes were measured in the testes by Western blotting and immunofluorescent labeling.

Results

The short-term BEP exposure resulted in a decrease in scavenger receptor class-B1 and an increase in luteinizing hormone receptor (LHR). The AC with or without BEP has increased the levels of LHR, 3β-hydroxysteroid dehydrogenase (3β-HSD) and 17β-HSD, but without significant changes in testosterone levels. The three cycles of BEP up-regulated the expression of steroidogenic acute regulatory protein (StAR) and down-regulated that of cholesterol side chain cleavage enzyme (P450scc), cytochrome p450 17A1 (Cyp17A1, recovered by the AC) and 17β-HSD, associated with significant reduction in testosterone levels. The three cycles with the recovery time led to decreases in LHR, StAR, P450scc and Cyp17A1 and increases in 3β-HSD and 17β-HSD. The AC did not enhance the recovery of the enzyme levels.

Conclusion

The three cycles of BEP treatment inhibit the testosterone synthesis pathway even after the recovery time. The AC recovers the effects of BEP chemotherapy on a few steroidogenic enzymes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Altun Z, Olgun Y, Ercetin P, Aktas S, Kirkim G, Serbetcioglu B, Olgun N, Guneri EA (2014) Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines. Cell Prolif 47(1):72–80. doi:10.1111/cpr.12080 PubMedCrossRef Altun Z, Olgun Y, Ercetin P, Aktas S, Kirkim G, Serbetcioglu B, Olgun N, Guneri EA (2014) Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines. Cell Prolif 47(1):72–80. doi:10.​1111/​cpr.​12080 PubMedCrossRef
3.
Zurück zum Zitat Kilarkaje N, Mousa AM, Al-Bader MM, Khan KM (2013) Antioxidants enhance the recovery of three cycles of bleomycin, etoposide, and cisplatin-induced testicular dysfunction, pituitary-testicular axis, and fertility in rats. Fertil Steril 100(4):1151–1159. doi:10.1016/j.fertnstert.2013.06.019 PubMedCrossRef Kilarkaje N, Mousa AM, Al-Bader MM, Khan KM (2013) Antioxidants enhance the recovery of three cycles of bleomycin, etoposide, and cisplatin-induced testicular dysfunction, pituitary-testicular axis, and fertility in rats. Fertil Steril 100(4):1151–1159. doi:10.​1016/​j.​fertnstert.​2013.​06.​019 PubMedCrossRef
5.
Zurück zum Zitat Howell SJ, Shalet SM (2001) Testicular function following chemotherapy. Hum Reprod Update 7(4):363–369PubMedCrossRef Howell SJ, Shalet SM (2001) Testicular function following chemotherapy. Hum Reprod Update 7(4):363–369PubMedCrossRef
6.
Zurück zum Zitat Poorman-Allen P, Backer LC, Adler ID, Westbrook-Collins B, Moses MJ, Allen JW (1990) Bleomycin effects on mouse meiotic chromosomes. Mutagenesis 5(6):573–581PubMedCrossRef Poorman-Allen P, Backer LC, Adler ID, Westbrook-Collins B, Moses MJ, Allen JW (1990) Bleomycin effects on mouse meiotic chromosomes. Mutagenesis 5(6):573–581PubMedCrossRef
7.
Zurück zum Zitat Howell SJ, Shalet SM (2002) Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 4(5):443–452PubMedCrossRef Howell SJ, Shalet SM (2002) Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 4(5):443–452PubMedCrossRef
8.
Zurück zum Zitat Marcon L, Hales BF, Robaire B (2008) Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat. J Androl 29(4):408–417. doi:10.2164/jandrol.107.004218 PubMedCrossRef Marcon L, Hales BF, Robaire B (2008) Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat. J Androl 29(4):408–417. doi:10.​2164/​jandrol.​107.​004218 PubMedCrossRef
9.
10.
Zurück zum Zitat Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102(15):1114–1130. doi:10.1093/jnci/djq216 PubMedCentralPubMedCrossRef Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fossa SD (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102(15):1114–1130. doi:10.​1093/​jnci/​djq216 PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118(12):3099–3111. doi:10.1002/ijc.21747 PubMedCrossRef Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H (2006) Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 118(12):3099–3111. doi:10.​1002/​ijc.​21747 PubMedCrossRef
14.
Zurück zum Zitat Maines MD, Sluss PM, Iscan M (1990) Cis-platinum-mediated decrease in serum testosterone is associated with depression of luteinizing hormone receptors and cytochrome P-450scc in rat testis. Endocrinology 126(5):2398–2406. doi:10.1210/endo-126-5-2398 PubMedCrossRef Maines MD, Sluss PM, Iscan M (1990) Cis-platinum-mediated decrease in serum testosterone is associated with depression of luteinizing hormone receptors and cytochrome P-450scc in rat testis. Endocrinology 126(5):2398–2406. doi:10.​1210/​endo-126-5-2398 PubMedCrossRef
15.
Zurück zum Zitat Rezvanfar MA, Shahverdi AR, Ahmadi A, Baeeri M, Mohammadirad A, Abdollahi M (2013) Protection of cisplatin-induced spermatotoxicity, DNA damage and chromatin abnormality by selenium nano-particles. Toxicol Appl Pharmacol 266(3):356–365. doi:10.1016/j.taap.2012.11.025 PubMedCrossRef Rezvanfar MA, Shahverdi AR, Ahmadi A, Baeeri M, Mohammadirad A, Abdollahi M (2013) Protection of cisplatin-induced spermatotoxicity, DNA damage and chromatin abnormality by selenium nano-particles. Toxicol Appl Pharmacol 266(3):356–365. doi:10.​1016/​j.​taap.​2012.​11.​025 PubMedCrossRef
19.
Zurück zum Zitat Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O (2010) Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58(1):134–140. doi:10.1016/j.eururo.2010.03.041 PubMedCrossRef Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O (2010) Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 58(1):134–140. doi:10.​1016/​j.​eururo.​2010.​03.​041 PubMedCrossRef
20.
21.
Zurück zum Zitat Palmieri G, Lotrecchiano G, Ricci G, Spiezia R, Lombardi G, Bianco AR, Torino G (1996) Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134(4):431–436PubMedCrossRef Palmieri G, Lotrecchiano G, Ricci G, Spiezia R, Lombardi G, Bianco AR, Torino G (1996) Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 134(4):431–436PubMedCrossRef
22.
23.
Zurück zum Zitat Bieber AM, Marcon L, Hales BF, Robaire B (2006) Effects of chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility. J Androl 27(2):189–200. doi:10.2164/jandrol.05103 PubMedCrossRef Bieber AM, Marcon L, Hales BF, Robaire B (2006) Effects of chemotherapeutic agents for testicular cancer on the male rat reproductive system, spermatozoa, and fertility. J Androl 27(2):189–200. doi:10.​2164/​jandrol.​05103 PubMedCrossRef
25.
26.
Zurück zum Zitat Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM (2001) Randomized placebo-controlled trial of testosterone replacement in men with mild leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 55(3):315–324. doi:10.1046/j.1365-2265.2001.01297.x CrossRef Howell SJ, Radford JA, Adams JE, Smets EM, Warburton R, Shalet SM (2001) Randomized placebo-controlled trial of testosterone replacement in men with mild leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 55(3):315–324. doi:10.​1046/​j.​1365-2265.​2001.​01297.​x CrossRef
27.
Zurück zum Zitat Payne AH, Youngblood GL (1995) Regulation of expression of steroidogenic enzymes in leydig cells. Biol Reprod 52(2):217–225PubMedCrossRef Payne AH, Youngblood GL (1995) Regulation of expression of steroidogenic enzymes in leydig cells. Biol Reprod 52(2):217–225PubMedCrossRef
28.
Zurück zum Zitat Svechnikov K, Izzo G, Landreh L, Weisser J, Soder O (2010) Endocrine disruptors and Leydig cell function. J Biomed Biotechnol. doi:10.1155/2010/684504 Svechnikov K, Izzo G, Landreh L, Weisser J, Soder O (2010) Endocrine disruptors and Leydig cell function. J Biomed Biotechnol. doi:10.​1155/​2010/​684504
29.
Zurück zum Zitat Delbes G, Hales BF, Robaire B (2007) Effects of the chemotherapy cocktail used to treat testicular cancer on sperm chromatin integrity. J Androl 28 (2):241–249; discussion 250–241. doi:10.2164/jandrol.106.001487 Delbes G, Hales BF, Robaire B (2007) Effects of the chemotherapy cocktail used to treat testicular cancer on sperm chromatin integrity. J Androl 28 (2):241–249; discussion 250–241. doi:10.​2164/​jandrol.​106.​001487
33.
Zurück zum Zitat Reaven E, Zhan L, Nomoto A, Leers-Sucheta S, Azhar S (2000) Expression and microvillar localization of scavenger receptor class B, type I (SR-BI) and selective cholesteryl ester uptake in Leydig cells from rat testis. J Lipid Res 41(3):343–356PubMed Reaven E, Zhan L, Nomoto A, Leers-Sucheta S, Azhar S (2000) Expression and microvillar localization of scavenger receptor class B, type I (SR-BI) and selective cholesteryl ester uptake in Leydig cells from rat testis. J Lipid Res 41(3):343–356PubMed
35.
Zurück zum Zitat Manna PR, Stocco DM (2005) Regulation of the steroidogenic acute regulatory protein expression: functional and physiological consequences. Curr Drug Targets Immune Endocr Metabol Disord 5(1):93–108PubMedCrossRef Manna PR, Stocco DM (2005) Regulation of the steroidogenic acute regulatory protein expression: functional and physiological consequences. Curr Drug Targets Immune Endocr Metabol Disord 5(1):93–108PubMedCrossRef
36.
Zurück zum Zitat Bogan RL, Davis TL, Niswender GD (2007) Peripheral-type benzodiazepine receptor (PBR) aggregation and absence of steroidogenic acute regulatory protein (StAR)/PBR association in the mitochondrial membrane as determined by bioluminescence resonance energy transfer (BRET). J Steroid Biochem Mol Biol 104(1–2):61–67. doi:10.1016/j.jsbmb.2006.10.007 PubMedCrossRef Bogan RL, Davis TL, Niswender GD (2007) Peripheral-type benzodiazepine receptor (PBR) aggregation and absence of steroidogenic acute regulatory protein (StAR)/PBR association in the mitochondrial membrane as determined by bioluminescence resonance energy transfer (BRET). J Steroid Biochem Mol Biol 104(1–2):61–67. doi:10.​1016/​j.​jsbmb.​2006.​10.​007 PubMedCrossRef
37.
Zurück zum Zitat Garcia MM, Acquier A, Suarez G, Gomez NV, Gorostizaga A, Mendez CF, Paz C (2012) Cisplatin inhibits testosterone synthesis by a mechanism that includes the action of reactive oxygen species (ROS) at the level of P450scc. Chem Biol Interact 199(3):185–191. doi:10.1016/j.cbi.2012.08.012 PubMedCrossRef Garcia MM, Acquier A, Suarez G, Gomez NV, Gorostizaga A, Mendez CF, Paz C (2012) Cisplatin inhibits testosterone synthesis by a mechanism that includes the action of reactive oxygen species (ROS) at the level of P450scc. Chem Biol Interact 199(3):185–191. doi:10.​1016/​j.​cbi.​2012.​08.​012 PubMedCrossRef
38.
Zurück zum Zitat Conley AJ, Bird IM (1997) The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Biol Reprod 56(4):789–799PubMedCrossRef Conley AJ, Bird IM (1997) The role of cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase in the integration of gonadal and adrenal steroidogenesis via the delta 5 and delta 4 pathways of steroidogenesis in mammals. Biol Reprod 56(4):789–799PubMedCrossRef
42.
Zurück zum Zitat Randall VA (1994) Role of 5 alpha-reductase in health and disease. Baillieres Clin Endocrinol Metab 8(2):405–431PubMedCrossRef Randall VA (1994) Role of 5 alpha-reductase in health and disease. Baillieres Clin Endocrinol Metab 8(2):405–431PubMedCrossRef
45.
Zurück zum Zitat Salem EA, Salem NA, Maarouf AM, Serefoglu EC, Hellstrom WJ (2012) Selenium and lycopene attenuate cisplatin-induced testicular toxicity associated with oxidative stress in wistar rats. Urology 79(5):1184-e1–1186-e1. doi:10.1016/j.urology.2011.12.006 CrossRef Salem EA, Salem NA, Maarouf AM, Serefoglu EC, Hellstrom WJ (2012) Selenium and lycopene attenuate cisplatin-induced testicular toxicity associated with oxidative stress in wistar rats. Urology 79(5):1184-e1–1186-e1. doi:10.​1016/​j.​urology.​2011.​12.​006 CrossRef
46.
Zurück zum Zitat Beytur A, Ciftci O, Oguz F, Oguzturk H, Yilmaz F (2012) Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats. Cancer Chemother Pharmacol 69(1):207–213. doi:10.1007/s00280-011-1692-y PubMedCrossRef Beytur A, Ciftci O, Oguz F, Oguzturk H, Yilmaz F (2012) Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats. Cancer Chemother Pharmacol 69(1):207–213. doi:10.​1007/​s00280-011-1692-y PubMedCrossRef
47.
Zurück zum Zitat Ilbey YO, Ozbek E, Cekmen M, Simsek A, Otunctemur A, Somay A (2009) Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways. Hum Reprod 24(7):1717–1725. doi:10.1093/humrep/dep058dep058 PubMedCrossRef Ilbey YO, Ozbek E, Cekmen M, Simsek A, Otunctemur A, Somay A (2009) Protective effect of curcumin in cisplatin-induced oxidative injury in rat testis: mitogen-activated protein kinase and nuclear factor-kappa B signaling pathways. Hum Reprod 24(7):1717–1725. doi:10.​1093/​humrep/​dep058dep058 PubMedCrossRef
Metadaten
Titel
Effects of combined treatment of α-tocopherol, l-ascorbic acid, selenium and zinc on bleomycin, etoposide and cisplatin-induced alterations in testosterone synthesis pathway in rats
verfasst von
Narayana Kilarkaje
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2014
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2592-8

Weitere Artikel der Ausgabe 6/2014

Cancer Chemotherapy and Pharmacology 6/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.